PBSV · XBRL financial data

Pharma-Bio Serv financial statements, every fiscal year

The same tables from 10 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PBSV's year ends in late October)

In thousands of dollars	FY 2020Oct 31, 2020	FY 2021Oct 31, 2021	FY 2022Oct 31, 2022	FY 2023Oct 31, 2023	FY 2024Oct 31, 2024	FY 2025Oct 31, 2025
Revenue	21,564	20,115	19,399	16,977	9,509	9,001
Cost of revenue	14,898	14,755	14,517	11,910	6,993	6,091
Gross profit	6,667	5,360	4,881	5,066	2,516	2,910
Selling, general and administrative	4,441	9,214	3,707	3,949	3,804	3,548
Operating income (loss)	2,226	(3,854)	1,175	1,117	(1,288)	(638)
Interest income	—	—	0	320	246	38
Other income (expense)	64	1,978	13	570	532	543
Income tax expense (benefit)	239	213	182	377	22	6
Net income (loss)	2,051	(2,089)	1,007	1,310	(778)	(100)
Earnings per share, diluted USD per share	—	—	—	0.06	(0.03)	(0.00)
Weighted average shares, basic thousands of shares	23,003	23,026	23,003	22,971	22,966	22,947
Weighted average shares, diluted thousands of shares	23,040	23,162	23,032	22,998	22,974	22,957

Fiscal years (PBSV's year ends in late October)

In thousands of dollars	FY 2020Oct 31, 2020	FY 2021Oct 31, 2021	FY 2022Oct 31, 2022	FY 2023Oct 31, 2023	FY 2024Oct 31, 2024	FY 2025Oct 31, 2025
Cash and cash equivalents	17,138	17,468	14,463	10,446	6,767	3,379
Marketable securities	—	—	0	4,531	5,978	7,475
Accounts receivable	9,728	4,613	4,983	3,941	2,511	2,361
Prepaid and other current assets	—	—	—	—	442	172
Total current assets	28,584	22,822	19,944	19,401	15,699	13,387
Property and equipment, net	218	106	74	33	169	116
Right-of-use asset	847	640	503	356	199	29
Total assets	29,919	23,921	20,651	19,902	16,292	13,653
Accounts payable	—	2,071	1,630	—	—	—
Total current liabilities	3,793	2,651	2,108	2,154	1,887	1,739
Lease liability, non-current	630	487	347	194	29	0
Total liabilities	7,202	5,007	4,093	3,775	2,577	1,739
Retained earnings	21,524	17,707	15,267	14,854	12,354	10,534
Total stockholders' equity	22,717	18,914	16,558	16,127	13,715	11,914
Total liabilities and equity	29,919	23,921	20,651	19,902	16,292	13,653
Common shares outstanding (cover page) thousands of shares	23,029	22,969	22,950	22,963	22,958	22,904

Fiscal years (PBSV's year ends in late October)

In thousands of dollars	FY 2020Oct 31, 2020	FY 2021Oct 31, 2021	FY 2022Oct 31, 2022	FY 2023Oct 31, 2023	FY 2024Oct 31, 2024	FY 2025Oct 31, 2025
Net income (loss)	2,051	(2,089)	1,007	1,310	(778)	(100)
Stock-based compensation	43	56	72	45	48	35
Depreciation and amortization	86	73	51	—	—	—
Net cash from operating activities	1,525	805	592	1,891	(567)	(215)
Purchases of property and equipment	56	11	19	7	160	7
Net cash from investing activities	(29)	1,297	(19)	(4,218)	(1,361)	(1,466)
Share repurchases	2	26	82	34	11	31
Dividends paid	1,725	1,727	3,447	1,724	1,722	1,720
Net cash from financing activities	194	(1,753)	(3,529)	(1,758)	(1,733)	(1,751)
Net change in cash	1,648	330	(3,006)	(4,017)	(3,679)	(3,388)

SIC 8742 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8742 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Pharma-Bio Serv	1,518	2,336	61	22.9M	—	Q3 FY26 10-QJul 31, 2026
Panamera Holdings	0	0	(45)*	79.9M	0.0 quarters	Q3 FY26 10-QApr 30, 2026
Nordicus Partners	5.8	not reported	(160)	19.4M	0.0 quarters	Q1 FY27 10-QJun 30, 2026
RTB Digital	492	2,328	(3,104)*	14.0M	0.2 quarters	Q2 FY26 10-Q/AJun 30, 2026
Elvictor Group	285	707	202*	834,042	—	Q2 FY26 10-QJun 30, 2026
Aeries Technology	6,069	21,918	4,824	not reported	—	Q1 FY27 10-QJun 30, 2026
Greenpro Capital	634	302	(338)*	18.1M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Mastech Digital	37,939	41,987	2,648*	12.0M	—	Q3 FY26 10-QSep 30, 2026
CISO Global	722	5,791	(69)*	45.5M	10.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.